News Contact Us Careers Get E-Mail alerts Search

ADMA Biologics, Inc.

  • Home
  • About Us
    • About ADMA Biologics
    • What We Do
    • Who We Are
      • Senior Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Compliance
  • Our Products
    • Products Overview
    • About Primary Immunodeficiency Disease (PI)
    • ASCENIV™
    • BIVIGAM®
    • Nabi-HB®
  • Our Pipeline
  • Immunotechnology
  • Plasma & IVIG
  • Medical Affairs
    • Medical Affairs Overview
    • Publications
  • Investors
    • Overview
    • Press Releases
      • Email Alerts
    • Company Info
      • Profile
      • Presentation
      • Management Team
      • Contacts
      • FAQ
    • Analyst Coverage
    • Events & Webcasts
    • Financial Info
      • Balance Sheets
      • Income Statement
      • Cash Flow
      • Financial Results
      • Annual Reports
    • Stock Info
      • Stock Data & Quote
      • Charts
      • Historical Data
    • SEC Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Board Committees
      • Documents
  • News
  • Contact Us
  • Careers
  • Get E-Mail alerts
  • Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

News

See below for our most recent and archived news events.

Investors

Investors

  • Overview
  • Press Releases
    • Email Alerts
  • Company Info
    • Profile
    • Presentation
    • Management Team
    • Contacts
    • FAQ
  • Analyst Coverage
  • Events & Webcasts
  • Financial Info
    • Balance Sheets
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
  • Stock Info
    • Stock Data & Quote
    • Charts
    • Historical Data
  • SEC Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Documents
  • home Home
  • Investors
  • Press Releases
  • Press Releases

  • Email Alerts

Click below for current and archived news related to the company.

ADMA Biologics, Inc. Announces Pricing of Initial Public Offering

Oct 17, 2013 9:11am EDT

ADMA Biologics Reports Second Quarter 2013 Financial and Operational Results

Aug 12, 2013 5:00pm EDT

ADMA Biologic’s Plasma Collection Facility Receives GHA Certification for the Sale of Source Plasma in Europe

Jun 18, 2013 8:00am EDT

ADMA Biologics Reports First Quarter 2013 Financial and Operational Results

May 14, 2013 5:00pm EDT

ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD Patients

Mar 07, 2013 8:30am EST

ADMA Biologics Reports 2012 Year End Financial and Operational Results

Mar 06, 2013 4:30pm EST

ADMA Biologics Executes Long-Term Manufacturing, Supply and License Agreements with Biotest

Jan 10, 2013 4:30pm EST

ADMA Biologics Secures Up To $6 Million Term Loan Commitment To Advance Phase III Study

Jan 07, 2013 8:30am EST

ADMA Biologics Reports 2012 Third Quarter Results

Nov 13, 2012 8:30am EST

ADMA Biologics to Present at the Rodman & Renshaw Annual Global Investment Conference

Sep 06, 2012 7:00am EDT
RSS
  • Prev
    • 1...
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    Next
    About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Medical Affairs Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS

    © Copyright 2021 ADMA Biologics, Inc.
    Ramsey, NJ Offices 201-478-5552
    Boca Raton, FL Offices 561-989-5800
    info@admabio.com

    Best places to work
    Bio NJ

    2020 Innovator Award

    50 fastest companies
    2019 Fast 500 Deloitte
    Bio Florida

    Named 2019 Company of the Year